➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Merck
AstraZeneca
Harvard Business School
Moodys

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GDC-0084


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for GDC-0084?

GDC-0084 is an investigational drug.

There have been 167 clinical trials for GDC-0084. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Leukemia. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are two US patents protecting this investigational drug and forty-three international patents.

Recent Clinical Trials for GDC-0084
TitleSponsorPhase
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENNational Cancer Institute (NCI)Phase 1/Phase 2
Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing PotentialGenentech, Inc.Phase 1
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to HormNational Cancer Institute (NCI)Phase 1/Phase 2

See all GDC-0084 clinical trials

Clinical Trial Summary for GDC-0084

Top disease conditions for GDC-0084
Top clinical trial sponsors for GDC-0084

See all GDC-0084 clinical trials

US Patents for GDC-0084

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0084   Start Trial Tricyclic PI3K inhibitor compounds and methods of use Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0084   Start Trial Tricyclic PI3K inhibitor compounds and methods of use Genentech, Inc. (South San Francisco, unknown)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GDC-0084

Drugname Country Document Number Estimated Expiration Related US Patent
GDC-0084 Argentina 084312 2030-12-16   Start Trial
GDC-0084 Australia 2011343712 2030-12-16   Start Trial
GDC-0084 Australia 2015268776 2030-12-16   Start Trial
GDC-0084 Brazil 112013014914 2030-12-16   Start Trial
GDC-0084 Canada 2820078 2030-12-16   Start Trial
GDC-0084 Chile 2013001093 2030-12-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
McKesson
Colorcon
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.